Search
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalAlthough originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. … Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic IndexSynonyms: 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarinLomustine
go.drugbank.com/drugs/DB01206ApprovedInvestigationalAn alkylating agent of value against both hematologic malignancies and solid tumors.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsSynonyms: 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosoureaBismuth subsalicylate
go.drugbank.com/drugs/DB01294ApprovedVet approved[L32318] Bismuth subsalicylate is a component of HELIDAC Therapy (bismuth subsalicylate, [metronidazole], and [tetracycline]), which is a treatment regimen indicated for the eradication of _H. pylori_ … [A230733] Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection.
Synonyms: 2-Hydroxy-benzo[1,3,2]dioxabismin-4-oneProducts: BİZMOPEPTOL MAX 1050 MG/30 ML ORAL SÜSPANSİYON, 240 ML, BİZMOPEPTOL 525 MG/30 ML ORAL SÜSPANSİYON , 240 MLIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Mixtures: ATECTURA®BREEZHALER®150/80 MCG POLVO PARA INHALACIÓN CÁPSULA DURA, ULTIBRO- BREEZHALER®Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRanolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsProducts: RANEXICOR ® 1000, CIVENISTU® 1000Levosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. … It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-RingProducts: SIMDAX 2.5 MG/ML KONSANTRE INF.COZ.5 ML X FLAKON, 1 ADET, DAXIM® 2.5 MG / MLStavudine
go.drugbank.com/drugs/DB00649ApprovedInvestigationalA dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Synonyms: 2',3'-Didehydro-3'-deoxythimidine, 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymineInternational brands: Ai Fu DingCycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Categories: Heterocyclic Compounds, 1-RingSynonyms: D-4-amino-3-isoxazolidone, D-4-amino-3-isoxazolidinoneZilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigationalZilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.
Synonyms: N2-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-L-VALYL-L-TYROSYL-3-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-L-ALANYL-L-.ALPHA., .-(2-(((4S)-4-CARBOXY-1-OXO-4-(1-OXOHEXADECYL)BUTYL)AMINO)ETHYL)-.OMEGA.-HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.Products: Zılbrysq 16,6 mg/0,416 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet), Zılbrysq 23 mg/0,574 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet)Dulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 ML